Elsevier

Gynecologic Oncology

Volume 112, Issue 1, January 2009, Pages 55-59
Gynecologic Oncology

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform

https://doi.org/10.1016/j.ygyno.2008.08.036Get rights and content

Abstract

Objective

To determine the utility of serum miRNAs as biomarkers for epithelial ovarian cancer.

Methods

Twenty-eight patients with histologically confirmed epithelial ovarian cancer were identified from a tissue and serum bank. Serum was collected prior to definitive therapy. Fifteen unmatched, healthy controls were used for comparison. Serum was obtained from all patients. RNA was extracted using a derivation of the single step Trizol method. The RNA from 9 cancer specimens was compared to 4 normal specimens with real-time PCR using the TaqMan Array Human MicroRNA panel. Twenty-one miRNAs were differentially expressed between normal and patient serum. Real-time PCR for the 21 individual miRNAs was performed on the remaining 19 cancer specimens and 11 normal specimens.

Results

Eight miRNAs of the original twenty-one were identified that were significantly differentially expressed between cancer and normal specimens using the comparative Ct method. MiRNAs-21, 92, 93, 126 and 29a were significantly over-expressed in the serum from cancer patients compared to controls (p < .01). MiRNAs-155, 127 and 99b were significantly under-expressed (p < .01). Additionally, miRs-21, 92 and 93 were over-expressed in 3 patients with normal pre-operative CA-125.

Conclusion

We demonstrate that the extraction of RNA and subsequent identification of miRNAs from the serum of individuals diagnosed with ovarian cancer is feasible. Real-time PCR-based microarray is a novel and practical means to performing high-throughput investigation of serum RNA samples. miRNAs-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential.

Introduction

In 2008, it is expected that 20,180 women will be diagnosed with ovarian cancer and 15,310 will succumb to the disease [1]. Ovarian cancer is a devastating illness in which only 20% of patients are diagnosed with stage I disease [2]. The poor prognosis associated with ovarian cancer is multi-factorial; a lack of minimally invasive, early detection tests, subtle symptom development and tumor chemo-resistance. Even with the advent of chemo-resistance assays it is still difficult to predict drug resistance and only 10–15% of patients will remain in prolonged remission after initial cytotoxic therapy.

While annual pelvic examination is widely practiced, it lacks the sensitivity to be used a screening strategy for ovarian cancer [3]. Women at high risk for ovarian cancer may typically undergo screening with trans-vaginal ultrasound and serum CA-125. CA-125, however, remains a poor marker for early stage disease with a documented sensitivity of 40% [4], [5]. Additionally, it has been shown that even in a high-risk, screened population, incident cases are still more likely to be advanced stage [6]. The identification of biomarkers that may assist in treatment planning and prediction of chemotherapy outcomes is highly desirable in this population of patients.

There is emerging research about the role of microRNAs in a variety of pathologic conditions; including both solid and hematologic malignancies. MicroRNAs (miRNAs) are small, 22–25 nucleotide non-coding sequences of RNA. These sequences control gene expression either by translational repression or degradation of the messenger RNA transcript after targeting the 3′UTR. Early studies with Caenorhabditis elegans showed that a great number of these sequences are highly conserved across all species, demonstrating the important roles that miRNAs play in cellular differentiation, proliferation and cell cycle control [7]. It is now recognized that miRNAs are frequently de-regulated in malignancy. Under-expressed miRNAs such as let-7 in lung cancer and mirs-15/16 in leukemia, are tumor suppressor genes, suppressing Ras and BCL2 respectively [8], [9]. Over-expressed miRNAs such as mir-21 and the cluster mir-17–92, are oncogenes (oncomirs), targeting tumor suppressors PTEN and E2F1 in solid and hematologic malignancies respectively [10], [11]. While miRNA research in gynecologic malignancies is in its infancy, the miRNA signature profile of ovarian cancer has recently been published [12], [13], [14].

The diagnostic and prognostic utility of circulating RNAs in both benign and malignant conditions has recently been revealed. Placental-associated circulating miRNAs correlate with pregnancy progression [15]. In malignant states, circulating mRNAs in renal cell carcinoma patients [16] as well as miRNAs from the serum of patients with diffuse large B cell lymphoma [17] have been shown to be stable and highly predictive of malignancy as well as survival. Recently, it has been demonstrated that the miRNA signature of circulating tumor exosomes of ovarian cancer patients demonstrates high correlation with miRNA expression of the primary tumor [18]. Ovarian cancer remains a disease for which improved non-invasive, serum screening tests are highly desirable. We offer a description of miRNA extraction from the serum of ovarian cancer patients, the differential expression of a number of these miRNAs between patients and healthy controls as well as a novel real-time PCR microarray detection method.

Section snippets

Methods

Following approval from the Institutional Review Board of The Ohio State University College of Medicine we analyzed serum samples from 28 patients with newly diagnosed ovarian cancer and 15 normal controls. These serum samples were collected at the time of initial consultation, prior to definitive surgical management and/or adjuvant therapy. The serum was obtained as part of a prospective tissue and serum procurement study and was stored at − 80 °C. Fresh serum was obtained from 15 healthy women

Results

Twenty-eight patients with epithelial ovarian cancer were included in this study. Stage breakdown was as follows: stage I-8 (28.5%), stage II-2 (7.1%), stage III-8 (28.5%) stage IV-10 (35.7%). Histologic breakdown was as follows: serous (60%), clear cell (21.2%), endometrioid (12%), mucinous (6%). Median age was 57 years (age range 34–79). Similar to most groups with ovarian cancer, the majority (66%) had stage III or IV disease, and was predominately (60%) serous histology.

Primary miRNA

Discussion

We demonstrate that the extraction of RNA and identification of miRNAs from the serum of individuals diagnosed with ovarian cancer is feasible. We offer the first description of using a real-time PCR, microarray platform to screen large numbers of miRNAs while minimizing the amount of RNA needed. Additionally, we provide evidence that miRNAs may potentially serve as early detection biomarkers in patients with normal CA-125.

With our approach we were able to create a profile that was subsequently

Conflict of interest statement

The authors have no conflicts of interest to declare.

Acknowledgment

This work was supported by the Jacquelyn L. Wells Endowment in Ovarian Cancer Research to D.E.C. and The Ohio State University Targets and Investments in Excellence Award to C.C.

References (28)

  • S.A. Cannistra

    Cancer of the ovary

    N. Engl. J. Med.

    (2004)
  • E.R. Myers et al.

    Management of adnexal masses

    Evid. Rep./ Technol. Assess.

    (2006)
  • I. Jacobs et al.

    Prevalence screening for ovarian cancer in post-menopausal women by CA-125 measurement and ultrasonography

    BMJ

    (1993)
  • G. Jannot et al.

    Tumor-related microRNAs functions in Caenorhabditis elegans

    Oncogene

    (2006)
  • Cited by (602)

    • Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond

      2023, Advances in Protein Chemistry and Structural Biology
    • Research progress of miR⁃21 in ovarian cancer

      2024, Medical Journal of Wuhan University
    View all citing articles on Scopus
    View full text